Identical to the Test product, XGEVA 120 mg solution for injection
BRCA-P/ABCSG 50
Phase 3 small_molecule active
Quick answer
Identical to the Test product, XGEVA 120 mg solution for injection for Prevention of breast cancer in women with a BRCA1 germline mutation is a Phase 3 program (small_molecule) at Rein Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rein Therapeutics
- Indication
- Prevention of breast cancer in women with a BRCA1 germline mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active